> ## Content Index > Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt > Use this file to discover other available public pages before exploring further. # HHS Proposes Doubling Buprenorphine Treatment Limit to 200 Patients - URL: https://www.theamericanquorum.com/hhs-buprenorphine-treatment-limit-200-patients/ - Published: 2016-04-03T03:59:00.000Z - Updated: 2016-04-03T03:59:00.000Z - Description: HHS proposed allowing qualified physicians to treat up to 200 patients with buprenorphine, doubling the federal cap while adding quality and diversion safeguards. - Author: Kenneth R. Deans Jr. - Tags: Healthcare, #Import 2026-08-30 06:29 **Qualified physicians could treat as many as 200 patients at a time with buprenorphine—double the current federal ceiling—under a proposed rule the Obama administration issued this week to widen access to medication for opioid addiction.** The proposal arrives as prescription painkillers and heroin are driving record overdose deaths, while many communities lack doctors authorized to provide office-based treatment. The Department of Health and Human Services said the change could extend care to tens of thousands of people, but it would reserve the higher limit for experienced physicians who meet added requirements for credentials, emergency coverage, behavioral-health services and reporting. Under the [proposed regulation published Wednesday](https://www.federalregister.gov/documents/2016/03/30/2016-07128/medication-assisted-treatment-for-opioid-use-disorders?ref=theamericanquorum.com), doctors who have held a federal waiver to treat up to 100 patients for at least one year could seek authorization for 200\. They would need board certification in addiction medicine or addiction psychiatry, or they would have to practice in a setting equipped to deliver a broader range of services. The rule is an attempt to relax a bottleneck created by the same system that made buprenorphine more accessible than methadone. Federal law allows trained physicians to prescribe the medication from ordinary medical offices, but it caps their patient panels—initially at 30 and, after additional experience, at 100—to reduce misuse and diversion. ## A treatment gap measured in millions More than two million Americans are estimated to have an opioid-use disorder involving prescription drugs or heroin. Yet only a minority receive medication-assisted treatment, which combines an approved drug with counseling and other support. HHS described that gap in its [account of federal opioid actions](https://aspe.hhs.gov/reports/opioid-abuse-us-hhs-actions-address-opioid-drug-related-overdoses-deaths-0?ref=theamericanquorum.com), identifying expanded treatment, better prescribing and wider availability of the overdose-reversal drug naloxone as the administration’s principal strategies. Buprenorphine, often combined with naloxone in a product intended to deter injection, binds to opioid receptors and suppresses withdrawal and craving. Its effects reach a ceiling, reducing—but not eliminating—the danger of respiratory depression compared with full opioid agonists. Unlike methadone for addiction, which generally must be dispensed through federally regulated programs, buprenorphine can be prescribed in a physician’s office after the doctor completes required training and obtains a waiver. That flexibility has brought treatment into primary-care practices and rural communities, but the patient ceilings can produce waiting lists. Some addiction specialists reach 100 patients quickly and must turn away people who are ready for care. The administration’s [March 29 fact sheet](https://obamawhitehouse.archives.gov/the-press-office/2016/03/29/fact-sheet-obama-administration-announces-additional-actions-address?ref=theamericanquorum.com) said doubling the cap is intended to expand access while preserving safeguards against diversion. The urgency is visible in mortality data. The Centers for Disease Control and Prevention reported 47,055 drug-overdose deaths in 2014, including 28,647 involving opioids. Earlier this month, the agency issued [12 recommendations for prescribing opioids for chronic pain](https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?ref=theamericanquorum.com), advising clinicians to prefer nonopioid therapy when possible and use the lowest effective dose. The treatment rule addresses the other side of the crisis: patients who have already developed dependence or addiction. ## Higher capacity tied to added obligations HHS did not propose an unrestricted increase. A physician seeking the 200-patient limit would have to show capacity to connect patients with counseling and ancillary services, provide 24-hour emergency coverage, use state prescription-drug monitoring programs and accept insurance, including Medicare and Medicaid, when appropriate. The [formal rulemaking docket](https://www.regulations.gov/document/SAMHSA-2016-0001-0001?ref=theamericanquorum.com) says the application would resemble the existing process for moving from 30 to 100 patients, with new attestations designed to protect quality. Physicians would also have to renew their authorization every three years and report information that allows the Substance Abuse and Mental Health Services Administration to monitor treatment practices. The requirements reflect two competing concerns. Treatment advocates argue that arbitrary numerical limits are inconsistent with the scale of the epidemic and unlike restrictions applied to most other chronic diseases. Regulators and some clinicians warn that rapid expansion without counseling, monitoring and diversion controls could produce high-volume practices that prescribe medication without adequate support. Buprenorphine itself can be misused, particularly by people without opioid tolerance, and diverted tablets have entered illicit markets. But diversion also can signal a shortage of legitimate treatment: people may obtain the medication outside medical channels to suppress withdrawal when they cannot find an available clinician. HHS is betting that carefully expanded legal access can reduce that pressure while improving oversight. The proposal allows temporary increases during emergencies and gives the government authority to suspend or revoke a higher limit when a physician fails to meet the conditions. It also stresses that medication should be offered as part of evidence-based care rather than as a stand-alone prescription. ## Money and training accompany the rule The cap change is one part of a broader package. The administration recently awarded $94 million to 271 community health centers to expand substance-use treatment, with an emphasis on medication-assisted care. The White House estimates that the grants will allow those centers to serve nearly 124,000 additional patients with substance-use disorders. SAMHSA is also offering $11 million to as many as 11 states to expand medication-assisted treatment. Its [grant announcement](https://www.samhsa.gov/sites/default/files/grants/pdf/ti-16-014.pdf?ref=theamericanquorum.com) directs states to increase access for people seeking care and to improve retention, recognizing that a regulatory waiver has little value if communities lack trained clinicians, pharmacies, counseling or stable financing. The National Association of State Alcohol and Drug Abuse Directors summarized the new [federal initiatives](https://nasadad.org/2016/03/federal-initiatives-to-address-the-opioid-crisis/?ref=theamericanquorum.com) as an integrated effort: the 200-patient proposal, health-center funding, state grants and clinician training. State agencies will play a central role because treatment capacity and overdose patterns vary sharply across regions. Administration officials have also called for Congress to provide $1.1 billion in new funding over two years, most of it for state grants to expand treatment. That request faces a separate legislative process, and the rule cannot by itself create a workforce or pay for care. It can, however, allow qualified doctors already treating 100 patients to accept more. ## Support—and pressure to go further The proposal drew immediate support from lawmakers and treatment advocates who have pressed the administration to loosen the ceiling. Senator Richard Durbin of Illinois said in a [March 29 statement](https://www.durbin.senate.gov/newsroom/press-releases/durbin-applauds-administration-action-to-address-the-prescription-opioid-abuse-and-heroin-epidemic?ref=theamericanquorum.com) that increasing access to evidence-based treatment is essential to confronting the prescription-opioid and heroin epidemic. Others contend that 200 remains too restrictive, particularly for specialized practices serving regions with few providers. The administration chose a measured increase while inviting public comment on eligibility, quality standards and reporting. HHS said it wants to estimate how many physicians would apply and whether the conditions would discourage participation. The rule will remain open for comment for 60 days. Until it becomes final, the 100-patient maximum remains in place. That means the near-term treatment gap will still depend on recruiting more doctors to obtain waivers, persuading clinicians with waivers to use their full capacity and funding the counseling and recovery services that medication alone cannot provide. Doubling the ceiling does not solve the opioid epidemic. It changes one practical constraint in a system where a patient’s chance of receiving effective treatment can turn on whether a nearby physician has an open slot. In communities losing people to overdoses, that arithmetic has become a matter of life and death.